These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 27374174)
1. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer. Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174 [TBL] [Abstract][Full Text] [Related]
2. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer. Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709 [TBL] [Abstract][Full Text] [Related]
3. CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection. Ji X; Shen Z; Zhao B; Yuan X; Zhu X Medicine (Baltimore); 2018 Mar; 97(10):e0101. PubMed ID: 29517684 [TBL] [Abstract][Full Text] [Related]
4. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470 [TBL] [Abstract][Full Text] [Related]
5. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer. Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery. Fang MY; Wang SY; Zheng YB; Gong LY; Bao WL; Gu DL; Mao WM Eur Rev Med Pharmacol Sci; 2014; 18(3):398-403. PubMed ID: 24563441 [TBL] [Abstract][Full Text] [Related]
7. Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion. Hao J; Zeltz C; Pintilie M; Li Q; Sakashita S; Wang T; Cabanero M; Martins-Filho SN; Wang DY; Pasko E; Venkat K; Joseph J; Raghavan V; Zhu CQ; Wang YH; Moghal N; Tsao MS; Navab R Neoplasia; 2019 May; 21(5):482-493. PubMed ID: 30978569 [TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-β1 and α-smooth muscle actin in stromal fibroblasts are associated with a poor prognosis in patients with clinical stage I-IIIA nonsmall cell lung cancer after curative resection. Chen Y; Zou L; Zhang Y; Chen Y; Xing P; Yang W; Li F; Ji X; Liu F; Lu X Tumour Biol; 2014 Jul; 35(7):6707-13. PubMed ID: 24711139 [TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Tsao MS; Yang Y; Marcus A; Liu N; Mou L Hum Pathol; 2001 Jan; 32(1):57-65. PubMed ID: 11172296 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. Schulze AB; Schmidt LH; Heitkötter B; Huss S; Mohr M; Marra A; Hillejan L; Görlich D; Barth PJ; Rehkämper J; Evers G Thorac Cancer; 2020 Jan; 11(1):120-129. PubMed ID: 31760702 [TBL] [Abstract][Full Text] [Related]
11. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer. Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y; Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428 [TBL] [Abstract][Full Text] [Related]
13. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer. Liu K; Chen HL; Gu MM; You QS Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Mao M; Wu Z; Chen J Biochem Biophys Res Commun; 2016 Sep; 478(2):649-55. PubMed ID: 27495872 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC. Liu L; Qu W; Zhong Z Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272 [TBL] [Abstract][Full Text] [Related]
16. Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer. Alcaraz J; Carrasco JL; Millares L; Luis IC; Fernández-Porras FJ; Martínez-Romero A; Diaz-Valdivia N; De Cos JS; Rami-Porta R; Seijo L; Ramírez J; Pajares MJ; Reguart N; Barreiro E; Monsó E Lung Cancer; 2019 Sep; 135():151-160. PubMed ID: 31446988 [TBL] [Abstract][Full Text] [Related]
17. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer. Liu J; Ping W; Zu Y; Sun W Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249 [TBL] [Abstract][Full Text] [Related]
18. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Han JY; Kim JY; Lee SH; Yoo NJ; Choi BG Lung Cancer; 2011 Nov; 74(2):293-9. PubMed ID: 21440951 [TBL] [Abstract][Full Text] [Related]
19. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients. Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406 [TBL] [Abstract][Full Text] [Related]
20. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers. Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]